X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (32) 32
humans (28) 28
male (21) 21
pharmacology & pharmacy (21) 21
rats (20) 20
nmda receptor (17) 17
stroke (17) 17
receptors, n-methyl-d-aspartate - antagonists & inhibitors (15) 15
neuroprotection (14) 14
stroke - drug therapy (14) 14
clinical neurology (13) 13
excitatory amino acid antagonists - pharmacology (13) 13
rats, sprague-dawley (13) 13
chemistry, medicinal (12) 12
indoles - pharmacology (12) 12
neuroprotective agents - therapeutic use (12) 12
glycine (10) 10
glycine - antagonists & inhibitors (10) 10
receptors, glycine - antagonists & inhibitors (10) 10
female (9) 9
index medicus (9) 9
neurosciences (9) 9
d-aspartate receptor (8) 8
glycine antagonist (8) 8
gv150526 (8) 8
indoles - therapeutic use (8) 8
mice (8) 8
aged (7) 7
clinical trials (7) 7
glycine agents - therapeutic use (7) 7
neuroprotective agents - pharmacology (7) 7
peripheral vascular disease (7) 7
acute stroke (6) 6
antagonists (6) 6
biochemistry & molecular biology (6) 6
brain ischemia - drug therapy (6) 6
chemistry, organic (6) 6
nmda (6) 6
receptors, n-methyl-d-aspartate - chemistry (6) 6
receptors, n-methyl-d-aspartate - metabolism (6) 6
structure-activity relationship (6) 6
treatment outcome (6) 6
cerebral-artery occlusion (5) 5
damage (5) 5
dose-response relationship, drug (5) 5
double-blind (5) 5
glutamate (5) 5
glycine antagonist gv150526 (5) 5
glycine site (5) 5
randomized controlled-trial (5) 5
rat-brain (5) 5
safety (5) 5
acute ischemic stroke (4) 4
amino-acid receptors (4) 4
brain (4) 4
brain - metabolism (4) 4
cells, cultured (4) 4
disease models, animal (4) 4
double-blind method (4) 4
drug therapy (4) 4
focal ischemia (4) 4
glycine - metabolism (4) 4
glycine agents - adverse effects (4) 4
glycine antagonists (4) 4
in-vivo (4) 4
indoles - administration & dosage (4) 4
indoles - adverse effects (4) 4
indoles - chemical synthesis (4) 4
indoles - pharmacokinetics (4) 4
ischemia (4) 4
ischemic stroke (4) 4
neurons - drug effects (4) 4
neurotoxicity (4) 4
pathological-changes (4) 4
rat (4) 4
rats, wistar (4) 4
receptors, n-methyl-d-aspartate - drug effects (4) 4
stroke - physiopathology (4) 4
acid (3) 3
acute disease (3) 3
antagonist (3) 3
anticonvulsants - chemical synthesis (3) 3
anticonvulsants - pharmacology (3) 3
area under curve (3) 3
binding sites (3) 3
binding sites - drug effects (3) 3
binding-site (3) 3
brain - drug effects (3) 3
cerebral cortex - drug effects (3) 3
cerebral infarction - drug therapy (3) 3
chemistry, multidisciplinary (3) 3
chromatography, high pressure liquid (3) 3
clinical trials as topic (3) 3
cortical neuronal morphology (3) 3
d-aspartate antagonist (3) 3
dizocilpine maleate - pharmacology (3) 3
drug interactions (3) 3
drugs (3) 3
excitatory amino acid antagonists - therapeutic use (3) 3
focal cerebral-ischemia (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neurosurgery, ISSN 0022-3085, 05/2013, Volume 118, Issue 5, pp. 1072 - 1085
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 04/2013, Volume 20, Issue 10, pp. 1241 - 1285
Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system.... 
ASIC | TRP | Central nervous system | P2X | KCNQ | NMDA | CNS | Ion channels | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | GATED SODIUM-CHANNELS | SUBTYPE-SELECTIVE AGONIST | D-ASPARTATE RECEPTOR | ion channels | ACID-SENSING ION-CHANNEL-1 | central nervous system | GLYCINE ANTAGONIST GV150526 | TARANTULA TOXIN PSALMOTOXIN-1 | TRAUMATIC BRAIN-INJURY | ISCHEMIC CELL-DEATH | PHARMACOLOGY & PHARMACY | PERIPHERAL NEUROPATHIC PAIN | TRANSGENIC MOUSE MODEL | Ligand-Gated Ion Channels - antagonists & inhibitors | Transient Receptor Potential Channels - antagonists & inhibitors | Calcium Channels - metabolism | Humans | Calcium Channel Blockers - therapeutic use | Potassium Channel Blockers - therapeutic use | Sodium Channel Blockers - pharmacology | Calcium Channel Blockers - pharmacology | Ion Channels - antagonists & inhibitors | Potassium Channels - metabolism | Animals | Ion Channels - metabolism | Sodium Channels - chemistry | Calcium Channels - chemistry | Central Nervous System Diseases - drug therapy | Sodium Channels - metabolism | Calcium Channel Blockers - chemistry | Sodium Channel Blockers - therapeutic use | Potassium Channels - chemistry | Sodium Channel Blockers - chemistry | Transient Receptor Potential Channels - metabolism | Ligand-Gated Ion Channels - metabolism | Potassium Channel Blockers - chemistry | Potassium Channel Blockers - pharmacology
Journal Article
Journal Article
Annals of Neurology, ISSN 0364-5134, 08/2005, Volume 58, Issue 2, pp. 182 - 193
Perinatal asphyxia can result in neuronal injury with long‐term neurological and behavioral consequences. Although hypothermia may provide some modest benefit,... 
CORTICAL CELL-CULTURE | NITROUS-OXIDE | MILD HYPOTHERMIA | GLYCINE CONCENTRATIONS | GLUCOSE DEPRIVATION | RECEPTOR ANTAGONIST GV150526 | ISCHEMIC BRAIN-DAMAGE | CEREBRAL-ISCHEMIA | MODERATE HYPOTHERMIA | NEUROSCIENCES | CLINICAL NEUROLOGY | PERINATAL ASPHYXIA | L-Lactate Dehydrogenase - metabolism | Neuroprotective Agents - therapeutic use | Motor Activity - physiology | Flow Cytometry - methods | Temperature | Recovery of Function - drug effects | Apoptosis - drug effects | Embryo, Mammalian | Xenon - therapeutic use | Asphyxia - prevention & control | Motor Activity - drug effects | Male | Body Temperature - physiology | Cerebral Cortex - cytology | Dose-Response Relationship, Drug | Proto-Oncogene Proteins c-bcl-2 - metabolism | Caspases - metabolism | Time Factors | Neurons - physiology | Caspase 3 | Hypoxia-Ischemia, Brain - therapy | Indoles - pharmacology | Neurons - drug effects | Disease Models, Animal | Animals, Newborn | bcl-X Protein | Blotting, Western - methods | Cells, Cultured | Rats | Excitatory Amino Acid Antagonists - pharmacology | bcl-2-Associated X Protein | Rats, Sprague-Dawley | Brain - drug effects | Gene Expression Regulation - drug effects | Immunohistochemistry - methods | Glucose - deficiency | Animals | Analysis of Variance | Necrosis - therapy | Brain - pathology | Gene Expression Regulation - radiation effects | Hypoxia | Mice | Mice, Inbred BALB C | Apoptosis - physiology | Hypothermia | Hypoxia-Ischemia, Brain - physiopathology
Journal Article
Stroke, ISSN 0039-2499, 10/2010, Volume 41, Issue 10, pp. S99 - S102
Intracerebral hemorrhage is a devastating neurological illness with few treatment options. In the past 10 years, 6 clinical trials have been completed... 
intracerebral hemorrhage | neuroprotection | clinical trials | MORTALITY | MULTICENTER | GAIN-AMERICA | RATS | PHASE-II | STATINS | CELECOXIB | CLINICAL NEUROLOGY | GLYCINE ANTAGONIST GV150526 | DOUBLE-BLIND | ACUTE STROKE | PERIPHERAL VASCULAR DISEASE | Neuroprotective Agents - therapeutic use | Cerebral Hemorrhage - drug therapy | Clinical Trials as Topic | Humans
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 04/2014, Volume 15, Issue 5, pp. 659 - 680
Introduction: Stroke is the world's second leading cause of death. Although recombinant tissue plasminogen activator is an effective treatment for cerebral... 
mitochondrial injury | hypoxia | thrombin | inhibit | preclinical experiments | antagonist | ischemic cascade | stroke | inflammatory cascade | cerebral ischemia | clinical trials | middle cerebral artery occlusion | small molecule inhibitor | Inhibit | Stroke | Middle cerebral artery occlusion | Clinical trials | Ischemic cascade | Thrombin | Small molecule inhibitor | Cerebral ischemia | Preclinical experiments | Hypoxia | Inflammatory cascade | Antagonist | Mitochondrial injury | RE-LY TRIAL | RANDOMIZED CONTROLLED-TRIAL | D-ASPARTATE RECEPTOR | ATRIAL-FIBRILLATION PATIENTS | GLYCINE ANTAGONIST GV150526 | MITOCHONDRIAL PERMEABILITY TRANSITION | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | H-3 ROLIPRAM BINDING | NF-KAPPA-B | ACUTE-STROKE | Neuroprotective Agents - therapeutic use | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Thrombosis - physiopathology | Humans | Calcium Channel Blockers - therapeutic use | Brain Ischemia - metabolism | Anticoagulants - therapeutic use | Brain Ischemia - physiopathology | Clinical Trials as Topic | Inflammation - immunology | Mitochondria - metabolism | Stroke - drug therapy | Brain Ischemia - immunology | Stroke - physiopathology | Antioxidants - therapeutic use | Stroke - metabolism | Thrombosis - metabolism | Animals | Inflammation - drug therapy | Brain Ischemia - drug therapy | Thrombosis - drug therapy | Drug Therapy, Combination | Stroke - immunology
Journal Article
Translational Stroke Research, ISSN 1868-4483, 12/2012, Volume 3, Issue 4, pp. 409 - 417
Journal Article
Stroke, ISSN 0039-2499, 02/2000, Volume 31, Issue 2, p. 358
GV150526, a selective glycine site antagonist, reduces infarct volume in rats with focal cerebral ischemia. Safety and efficacy in humans with acute stroke are... 
Injections, Intravenous | Double-Blind Method | Glycine Agents - administration & dosage | Humans | Middle Aged | Rats | Male | Treatment Outcome | Stroke - drug therapy | North America | Stroke - physiopathology | Indoles - administration & dosage | Animals | Indoles - adverse effects | Aged, 80 and over | Female | Glycine Agents - adverse effects | Aged
Journal Article
Journal Article